Rapid Nexus Secures VA and DoD Contracts for Hemastyl® Deployment
Rapid Nexus has secured contracts with the VA and DoD for its FDA-cleared wound treatment, Hemastyl®, which will begin commercial deployment on May 1, 2026. This marks a significant milestone towards real-world clinical use in managing complex wound care for veterans and service members, aiming to improve healing by addressing underlying tissue conditions rather than just surface symptoms.
Deployment across VA and Department of Defense systems brings Rapid Nexus into real-world clinical use, expanding access to its FDA-cleared Hemastyl® treatment for complex wound cases BREA, Calif., April 29, 2026 /PRNewswire/ — Rapid Nexus Nanotech Wound Solutions, Inc., a…